Exploring new strategy in erenumab therapy for migraine patients

Neurol Sci. 2020 Dec;41(Suppl 2):507-508. doi: 10.1007/s10072-020-04678-x.

Authors

Fabio Frediani¹, Giacomo D'Arrigo², Alberto Galli², Riccardo Altavilla², Paola Di Fiore²

Affiliations

¹ Headache Center, Neurology & Stroke Unit, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy. fabio.frediani@asst-santipaolocarlo.it.
² Headache Center, Neurology & Stroke Unit, San Carlo Borromeo Hospital, ASST Santi Paolo e Carlo, Milan, Italy.

PMID: 32857326
DOI: 10.1007/s10072-020-04678-x

No abstract available

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Calcitonin Gene-Related Peptide Receptor Antagonists
Humans
Migraine Disorders* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Calcitonin Gene-Related Peptide Receptor Antagonists
erenumab